April 15, 2016
Sanofi and its global business unit Sanofi Pasteur has announced that Strategic Advisory Group of Experts on Immunization (SAGE) convened by the World Health Organization (WHO) has issued its recommendations to the WHO on the use of Sanofi Pasteur’s dengue vaccine Dengvaxia®. According to WHO SAGE, a strong public health benefit can be gained by this dengue vaccine.
The SAGE also advises that countries with high dengue transmission should consider introduction of the dengue vaccine as part of an integrated disease prevention strategy for lowering their dengue disease burden effectively. Endemic countries can achieve the WHO objectives to reduce dengue morbidity by 25% and mortality by 50% by 2020 if they can successfully introduce dengue immunization alongside other prevention efforts.
“We welcome these recommendations for Dengvaxia® from SAGE, the advisory group to the WHO, for vaccines and immunization. “Dengvaxia® has been approved in four countries already, including Mexico and Brazil, which have regulatory authorities recognized by the WHO. These WHO SAGE recommendations further validate the scientific and medical value of Dengvaxia® and send a clear message to endemic countries about the strong public health benefit to be gained by introducing the dengue vaccine in integrated disease management efforts to combat their dengue burden,” said Elias Zerhouni, MD, President of global R&D, Sanofi.
As demonstrated during 25 months of follow-up of phase III efficacy studies, the anticipated impact of Dengvaxia® vaccine on the disease of dengue fever is expected to stem from the proven ability of this vaccine to prevent 8 out of 10 dengue hospitalizations and up to 93% of severe dengue cases, including dengue hemorrhagic fever.